Nancy Ghattas, Vice President, US Oncology Commercial Franchise Head, Immuno Oncology (GI, Lung, GYN, GU) at AstraZeneca, shared on LinkedIn:
“Although ESMO26 may have ended, its momentum continues – from sharing unprecedented data, connecting across the global oncology community, and uniting around our ambition to defeat cancer.
Behind the data, the AstraZeneca team is working tirelessly to serve thousands of patients to deliver on the promise of these scientific discoveries.
Their commitment is inspiring, and their drive to transform patient outcomes is changing lives.
Together, we’re rewriting the future of cancer care.”
Other articles about ESMO26 and AstraZeneca on OncoDaily.